The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1357
Pegloticase (Krystexxa) for Treatment of Refractory Gout
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Pegloticase (Krystexxa – Savient), a PEGylated urate oxidase enzyme, has been approved by the FDA for intravenous (IV) treatment of chronic symptomatic gout in adults who have not responded to maximum doses of a xanthine oxidase inhibitor, such as allopurinol (Zyloprim, and others). Pegloticase is the second new drug approved for gout in more than 40 years; a new xanthine oxidase inhibitor, febuxostat (Uloric), was approved in 2009.1

MECHANISM OF ACTION — Unlike the xanthine oxidase inhibitors, which decrease serum concentrations of uric acid by inhibiting its synthesis, pegloticase reduces serum uric acid by catalyzing oxidation of uric acid into allantoin, an inert water-soluble purine metabolite that is cleared by the kidney.

PHARMACOLOGY — A single infusion of pegloticase produces maximal suppression of plasma urate ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pegloticase (Krystexxa) for Treatment of Refractory Gout
Article code: 1357b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian